Dear Dr. Hoff:


We acknowledge receipt of your submissions dated May 12, 2005 and June 15, 2005.

This supplemental application proposes revisions to the DESCRIPTION, PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of the package insert. The information regarding sevoflurane degradation products and pathways and the language related to replacement of desiccated CO₂ absorbent canisters is added.

We have completed our review of this supplemental new drug application, as amended, and it is approved effective on the date of this letter with the revision listed below.

As agreed to by you, the second sentence of the last paragraph of the DESCRIPTION section will be revised as follows:

Concentrations of formaldehyde observed with desiccated soda lime in this experimental anesthesia respiratory circuit were consistent with levels that could potentially result in respiratory irritation.

The final printed labeling (FPL) must be identical to the labeling submitted on June 15, 2005.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “FPL for approved NDA 20-478/S-013.” Approval of this submission by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Meyer, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

Bob A. Rappaport, M.D.
Division Director
Division of Anesthesia, Analgesia, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Bob Rappaport
6/21/05 01:40:43 PM